Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazunobu Kato

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Frontiers in Bioscience : a Journal and Virtual Library|May 25, 2006
Critical overview of mitochondrial nitric-oxide synthaseKazunobu Kato, Cecilia Giulivi
The Biochemical Journal|August 5, 2009
Nitration of tyrosine residues 368 and 345 in the beta-subunit elicits FoF1-ATPase activity lossYasuko Fujisawa, Kazunobu Kato, Cecilia Giulivi
American Journal of Physiology. Cell Physiology|August 4, 2006
Nitric oxide regulation of mitochondrial oxygen consumption I: cellular physiologyCecilia Giulivi, Kazunobu Kato, Christopher Eric Cooper
Cancer Chemotherapy and Pharmacology|January 7, 2015
Dosing algorithm revisit for busulfan following IV infusionYanlin Wang, Kazunobu Kato, Christopher Le Gallo, et al.
Blood|June 24, 2004
Genetic deletion of mouse platelet glycoprotein Ibbeta produces a Bernard-Soulier phenotype with increased alpha-granule sizeKazunobu Kato, Constantino Martinez, Susan Russell, et al.
The Journal of Biological Chemistry|July 26, 2003
Convulxin binds to native, human glycoprotein Ib alphaSachiko Kanaji, Taisuke Kanaji, Kenichi Furihata, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2002
A prototypic platelet septin and its participation in secretionJudith Dent, Kazunobu Kato, Xiao-Rong Peng, et al.
Blood|May 10, 2003
The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletionKazunobu Kato, Taisuke Kanaji, Susan Russell, et al.
Investigational New Drugs|March 5, 2025
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphomaMelissa Johnson, David Hong, Irene Braña, et al.
Blood|September 23, 2022
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphomaKoji Izutsu, Shinichi Makita, Kisato Nosaka, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Frontiers in Bioscience : a Journal and Virtual Library|May 25, 2006
Critical overview of mitochondrial nitric-oxide synthaseKazunobu Kato, Cecilia Giulivi
The Biochemical Journal|August 5, 2009
Nitration of tyrosine residues 368 and 345 in the beta-subunit elicits FoF1-ATPase activity lossYasuko Fujisawa, Kazunobu Kato, Cecilia Giulivi
American Journal of Physiology. Cell Physiology|August 4, 2006
Nitric oxide regulation of mitochondrial oxygen consumption I: cellular physiologyCecilia Giulivi, Kazunobu Kato, Christopher Eric Cooper
Cancer Chemotherapy and Pharmacology|January 7, 2015
Dosing algorithm revisit for busulfan following IV infusionYanlin Wang, Kazunobu Kato, Christopher Le Gallo, et al.
Blood|June 24, 2004
Genetic deletion of mouse platelet glycoprotein Ibbeta produces a Bernard-Soulier phenotype with increased alpha-granule sizeKazunobu Kato, Constantino Martinez, Susan Russell, et al.
The Journal of Biological Chemistry|July 26, 2003
Convulxin binds to native, human glycoprotein Ib alphaSachiko Kanaji, Taisuke Kanaji, Kenichi Furihata, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2002
A prototypic platelet septin and its participation in secretionJudith Dent, Kazunobu Kato, Xiao-Rong Peng, et al.
Blood|May 10, 2003
The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletionKazunobu Kato, Taisuke Kanaji, Susan Russell, et al.
Investigational New Drugs|March 5, 2025
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphomaMelissa Johnson, David Hong, Irene Braña, et al.
Blood|September 23, 2022
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphomaKoji Izutsu, Shinichi Makita, Kisato Nosaka, et al.
Pageof 2